NICE has recommended Gilead’s Epclusa as a treatment option for all genotypes of hepatitis C in first draft guidance. Trial data has shown recently-approved Epclusa (sofosbuvir+velpatasvir) gives cure ...

If you’re considering treatment for hepatitis C, your doctor may recommend Epclusa. It’s a prescription drug that’s used in adults and some children to treat hepatitis C, which is caused by hepatitis ...

If you have hepatitis C, your doctor may prescribe an antiviral medication, such as Mavyret (glecaprevir and pibrentasvir) or Epclusa (velpatasvir and sofosbuvir). Hepatitis C is an infection caused ...

Epclusa (sofosbuvir/velpatasvir) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat hepatitis C, which is an ...

After reviewing the evidence for all approved hepatitis C virus treatments, Advera Health has determined that Gilead Sciences’ newly approved, pan-genomic Epclusa has a similar safety profile as ...

Hepatitis C is one of the most common viral infections in the United States. Without treatment, hepatitis C can lead to severe health issues. Epclusa was approved to treat chronic hepatitis C by the ...

Gilead Sciences announced that its subsidiary, Asegua Therapeutics, will launch authorized generic versions of Epclusa (sofosbuvir, velpatasvir) and Harvoni (ledipasvir, sofosbuvir), both indicated ...

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate ...

Please provide your email address to receive an email when new articles are posted on . Epclusa showed a manageable drug interaction profile with commonly used antiretrovirals in treating patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced it has approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults ...